3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
117
Stomach Neoplasms
20
HER2-positive Breast Cancer
14
Neoplasm Metastasis
13
Neoplasms
12
Colorectal Neoplasms
11
Esophageal Neoplasms
9
Triple Negative Breast Neoplasms
5
Lung Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Rectal Neoplasms
4
Ovarian Neoplasms
4
Meningeal Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Adenocarcinoma Of Esophagus
4
Uterine Cervical Neoplasms
3
Salivary Gland Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Meningeal Carcinomatosis
3
Lymphoma, Non-Hodgkin
3
Inflammatory Breast Neoplasms
3
Hematologic Neoplasms
3
Gallbladder Neoplasms
3
Breast Diseases
3
Anatomic Stage I Breast Cancer AJCC v8
3
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Trastuzumab
×
1 year
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled